Table 2 Comparison of initial and follow up measures of the 2-HE/16alpha-HE ratio in those patients treated with Lucentia Peak® and those patients who were untreated control subjects
From: Multi-nutrient supplement improves hormone ratio associated with cancer risk
Peak group | 2-HE | 16alpha-HE | Ratio | Control group | 2-HE | 16alpha-HE | Ratio |
|---|---|---|---|---|---|---|---|
Pre Mean | 170.0 | 464.8 | 0.38 | Initial Mean | 321.8 | 525.4 | 0.65 |
Pre SD | 96.2 | 137.5 | 0.21 | Initial SD | 191.4 | 346.2 | 0.34 |
Post Mean | 262.4 | 490.0 | 0.57 | Follow up Mean | 278.7 | 479.2 | 0.64 |
Post SD | 117.7 | 173.0 | 0.27 | Follow up SD | 131.1 | 174.6 | 0.33 |
p-value | < 0.0001 | 0.1380 | < 0.0001 | 0.301 | 0.290 | 0.474 |